An Italian study consisting of 63 end-stage NSCLC patients with EGFR mutation treated with EGFR-TKIs suggested that patients with NLR lower than 3.5 had longer progression-free survival (PFS) and overall survival (OS) in comparison with those with NLR higher than 3.5 (PFS: hazard ratio (HR) = 2.275, P value = 0.007; OS: HR = 2.699, P value = 0.018) [5]. Here, EGFR is linked to non-small cell lung carcinoma.